🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Germany / NCT07815067
Starting soon Phase 1

A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity

NCT07815067 · tracked via the Priya Life Science Germany tracker
Phase
Phase 1
Started
2026-09-07
Last updated
2026-09-11

Condition(s) studied

OverweightObesity

Investigational drug(s) / intervention(s)

Zenagamtide injection →Zenagamtide tablet →

Zenagamtide injection: Zenagamtide will be administered to one of the body parts: thigh, abdomen or upper arm

Zenagamtide tablet: Zenagamtide tablet will be taken in the morning in fasted state.

Study summary

The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator. * Unusual meal habits (including, but not limited to, eating disorders) and special diet * HbA1c more than or equal to (≥) 6.5 percent (%) \[48 (nanomoles per mole) mmol/mol\] at screening.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Charité - Campus Charité Mitte - Charité Research Organisation GmbH Berlin Germany

More Novo Nordisk A/S trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07815067 on ClinicalTrials.gov ↗ ← All trials in Germany